For Linux server and infrastructure operators, we have organized the vulnerabilities newly reported in the past 24 hours (JST ...
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund 6.56M Jun 30, 2026 1.05% 16,064,302 ...
A critical vulnerability dubbed Java4Shell in OpenJDK, the open-source implementation of Java, can allow unauthenticated ...
Java4Shell (CVE-2026-114938) is a critical OpenJDK Base64 decoder bug that can lead to RCE. See who’s affected, how to check ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Doug ...
Recursion Pharmaceuticals said on November 18, 2026 that it had aligned with the U.S. Food and Drug Administration on a ...
Transformer on MSNOpinion

Policy can still work on short timelines

Transformer Weekly: California makes a bid to regulate AI, a new FRONTIER ACT, and Anthropic’s record-breaking IPO ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...